Edition:
United Kingdom

Tamara Mathias

Jeff Mason is a White House Correspondent for Reuters and the 2016-2017 president of the White House Correspondents’ Association. He was the lead Reuters correspondent for President Barack Obama's 2012 campaign and interviewed the president at the White House in 2015. Jeff has been based in Washington since 2008, when he covered the historic race between Obama, Hillary Clinton and John McCain. Jeff started his career in Frankfurt, Germany, where he covered the airline industry before moving to Brussels, Belgium, where he covered the European Union. He is a Colorado native, proud graduate of Northwestern University and former Fulbright scholar.

Twitter handle: @jeffmason1

16 Jan 2018

Positive Keytruda lung cancer data sends Merck shares up 6 percent

Positive lung cancer results for Merck & Co Inc's blockbuster drug Keytruda assuaged investor concerns about delays in testing and the withdrawal of an application for European use of the drug, sending the drugmaker's shares up more than 6 percent.

08 Jan 2018

Axovant shares plunge after key dementia drug programme scrapped

Axovant Sciences Ltd's shares plunged nearly 50 percent on Monday after the company scrapped its lead experimental dementia treatment following back-to-back trial failures.

05 Jan 2018

Future of Kala Pharma's dry eye drug uncertain after mixed results

Mixed results from two late-stage studies testing Kala Pharmaceuticals Inc's drug to provide temporary relief from dry eye disease cast doubt on the drug's path forward and sent shares down 16 percent in early trading on Friday.

26 Dec 2017

Mallinckrodt to buy Sucampo for about $840 million

Mallinckrodt Plc said on Tuesday it would buy Sucampo Pharmaceuticals Inc for about $840 million (£628.8 million) to snap up constipation drug Amitiza and a clutch of experimental rare disease treatments, as it battles declining sales of its biggest drug, Acthar.

14 Dec 2017

Pfizer's second biosimilar of J&J's Remicade wins U.S. FDA approval

The U.S. Food and Drug Administration approved Pfizer Inc's second biosimilar to Johnson & Johnson's blockbuster rheumatoid arthritis drug, Remicade, the company said on Wednesday.

14 Nov 2017

Loxo signs lucrative cancer drug deal with Bayer, but shares fall

Loxo Oncology on Tuesday signed a collaboration agreement for its promising cancer drugs with Germany's Bayer AG that could be worth up to $1.55 billion to the tiny U.S. company, but its shares fell 11 percent as the deal appeared to end near-term likelihood of a takeover.

09 Nov 2017

Sage soars as postpartum depression drug moves closer to approval

Sage Therapeutics Inc's shares surged to a record on Thursday after its postpartum depression drug succeeded in two late-stage studies, paving the way for it to bring to market the first FDA-approved treatment for the disorder.

02 Nov 2017

AmerisourceBergen expects tumbling generic drug prices to settle

AmerisourceBergen Corp said it expects stubbornly low generic drug prices, which have plagued drugmakers and wholesalers, to not deteriorate further next year, and brushed off concerns about Amazon's possible entry into the industry.

01 Nov 2017

Allergan assuages shareholder fears over losing Restasis patent

Allergan Plc on Wednesday reassured shareholders that it would return to earnings growth in 2019 after losing a major patent ruling last month on its second-most important drug, dry-eye treatment Restasis. | Video

30 Oct 2017

Drugmaker Endo estimates profit above Street view; shares surge

Endo International Plc on Monday gave a glimpse of a quarter that could help ease investor concerns when it announced preliminary earnings well above market estimates, sending the generic-drug maker's shares up as much as 18 percent.

  • Europe
  • U.S.
  • Asia
  • Sectors
Stock Search
FTSE 100 7,730.79 + 29.83 +0.39%
DAX 13,434.45 + 153.02 +1.15%
CAC 40 5,526.51 + 31.68 +0.58%
TR Europe 197.16 + 1.25 +0.64%
GBP/USD 1.3857 +0.06%
GBP/EUR 1.1337 +0.06%
EUR/USD 1.2220 +0.00%
Gold 1,333.00 +7.00 +0.53%
Oil 63.57 -0.38 -0.59%
Corn 352.50 +1.00 +0.28%